Related Experiment Video
Updated: Mar 7, 2026
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic
Zhanpeng Cao1, Wei Ma1, Chuanchuan Liu2
1Department of Cardiothoracic Surgery, Qinghai University Affiliated Hospital, Xining, Qinghai, 810001, China.
Purpose:
This review aims to explore the role of hyperuricemia in the pathogenesis of hypoxic pulmonary hypertension (HPH), focusing on its contribution to pulmonary vascular remodeling and evaluating the potential of uric acid-lowering strategies.
Methods:
A comprehensive review of the literature was conducted to assess the impact of elevated uric acid levels on HPH. The review highlights uric acid's effects on smooth muscle cell proliferation, endothelial dysfunction, oxidative stress, and inflammation. It also examines the interference of uric acid with nitric oxide signaling and its activation of the renin-angiotensin system under hypoxic conditions.
Results:
The literature indicates a significant correlation between elevated serum uric acid levels and the severity of HPH. Uric acid contributes to vascular remodeling by promoting oxidative stress, inflammation, and endothelial dysfunction. Preclinical evidence suggests that uric acid-lowering interventions, when combined with antioxidant or anti-inflammatory therapies, may reduce pulmonary vascular damage and improve outcomes.
Conclusion:
Uric acid represents a potential therapeutic target for HPH. Uric acid-lowering strategies, although promising, require further clinical validation. A deeper understanding of the molecular mechanisms underlying hyperuricemia in HPH may facilitate the development of targeted diagnostic and therapeutic approaches.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...